Actionable news
All posts from Actionable news
Actionable news in ZYNE: Zynerba Pharmeceuticals Inc,

Zynerba Midstage Cannabinoid Trial Falls Short

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating ZYN002 (cannabidiol [CBD] gel) for the treatment of knee pain due to osteoarthritis. Unfortunately, the study did not meet its primary endpoint of reduction from baseline in the weekly mean of the 24-hour average worst pain score at week 12 for either dose.

Statistically significant results were achieved for a number of secondary endpoints. Importantly, the composite responder analysis (defined as a greater than or equal to 30% reduction in worst average daily pain scores and a greater than or equal to...